

Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

### Vascular Research Initiatives Conference (VRIC) 2022 Translational Immunology and Cardiovascular Disease

### 22-VIRC-455-AHA-VD

01

### The Histone Methyl Transferase (SUV39H1) Promotes Smooth Muscle Cell Dedifferentiation

**Payel Chatterjee,**<sup>1</sup> Raja Chakraborty,<sup>1</sup> Yi Xie,<sup>1</sup> Ashley Sizer,<sup>2</sup> John Hwa,<sup>2</sup> Kathleen A. Martin<sup>2</sup>. <sup>1</sup>Yale University, New Haven, CT; <sup>2</sup>Yale School of Medicine, New Haven, CT

**Objectives:** The phenotypic plasticity of vascular smooth muscle cells (VSMCs) is central to growth and remodeling processes, but also contributes to the pathology of atherosclerosis, restenosis, and other cardiovascular diseases. This ability of VSMCs to reversibly differentiate and dedifferentiate is incompletely understood. SUV39H1, a histone methyl-transferase, specifically trimethylates Lys-9 of histone H3 (H3K9me3), resulting in epigenetic transcriptional repression. We hypothesized that SUV39H1 plays a role in VSMC phenotypic switching.

Methods: Using knockdown, quantitative polymerase chain reaction, Western blot, chromatin immunoprecipitation, RNA sequencing, and murine vascular injury to determine the role of SUV39H1 in VSMC plasticity.

Results: A quantitative polymerase chain reaction array screen of epigenetic regulators revealed that SUV39H1 is upregulated with platelet-derived growth factor -induced dedifferentiation, but downregulated with rapamycin-induced differentiation in human coronary artery smooth muscle cells. SUV39H1 knockdown promoted differentiation measured by increased contractile gene, protein expression, enhanced contractility, decreased migration, proliferation, and dedifferentiationassociated gene expression. RNA sequencing transcriptomics confirmed changes in multiple pathways consistent with a role for SUV39H1 in promoting human coronary artery smooth muscle cell dedifferentiation. Mechanistically, SUV39H1 knockdown suppressed expression of KLF4, the master transcriptional regulator of VSMC dedifferentiation, decreasing KLF4 messenger RNA stability and upregulating miRNA143, a known repressor of KLF4. siSUV39H1 also increased expression of KDM4a, a JMJD family lysine demethylase that targets H3K9me3. Chromatin immunoprecipitation assays at contractile gene promoters showed significant decrease in the H3K9me3 mark and increase in H3K27Ac after SUV39H1 knockdown. In vivo, we noted a significant increase in SUV39H1 and H3K9me3 expression in murine carotid artery ligation induced intimal hyperplasia.

**Conclusions:** We identify SUV39H1 as an epigenetic regulator of VSMC phenotype whose expression and activity increase with dedifferentiation in vitro and in vivo. Platelet-derived growth factor promotes H3K9me3 repressive marks at contractile genes by promoting expression of SUV39H1, which also inhibits the KDM4a. Understanding the role of SUV39H1 in VSMC plasticity may reveal new therapeutic strategies for treating vascular diseases.

Author Disclosures: P. Chatterjee: Nothing to disclose; R. Chakraborty: Nothing to disclose; Y. Xie: Nothing to disclose; A. Sizer: Nothing to disclose; J. Hwa: Nothing to disclose; K.A. Martin: Nothing to disclose

#### 22-VIRC-527-AHA-VD

### Single Cell Gene Expression Of Brachial Artery In Response To Increased Shear Stress

Jared Rozowsky, Qiongyao Hu, Kerri O'Malley, Erik Anderson, Brian Fazzone, Scott A. Berceli. University of Florida, Gainesville, FL


**Objective:** Blood flow dynamics modulate vascular development, homeostasis, and contribute to vascular pathobiology. However, it is unknown how shear stress influences cellular transcriptomics of the arterial wall. Two-stage hemodialysis access surgeries provide an opportunity to compare native vessels with vessels after exposure to significantly altered hemodynamics.

**Methods:** Single-cell sequencing was performed on brachial artery samples obtained from three patients at the time of first and second stage surgeries. Arterial cellular composition and temporal changes in gene expression were quantified after sequencing and functional analyses were performed on differentially expressed genes.

Results: Compositional changes and gene expression dynamics were highest in the smooth muscle cell (SMC) populations followed by

fibroblasts. SMCs were clustered into contractile (classical) and modified  $\,64$ populations, with the latter having lower expression of contractile 65 markers. Downregulation of the transcription factor ARNTL was the 66most significant controller in contractile SMCs and fibroblasts, and sec-67 ond behind heat-inducible factor 1a in modified SMCs. Macrophages had a significant increase in composition, but few dynamic genes sug- 68 gest a return to quiescence. Endothelial cells showed minimal changes 69with dynamic genes responding to mechanical stimulus. An ingenuity  $\,70$ pathway analysis revealed activation of EIF2 signaling in both SMC and 71 fibroblast clusters, promoting translation. The top divergent pathway 72 among SMC clusters is PI3/AKT signaling, with increased vascular remod-73 eling, proliferation, and cell death in the contractile group.

**Conclusions:** Cellular processes are overall downregulated in modified 74 SMCs, which represent the majority of SMCs after vascular adaption. This 75 study is the first single-cell characterization of normal human artery and its cellular response to increased hemodynamic forces, specifically detailing cellular compositional changes and their associated dynamic genes



#### 22-VIRC-518-AHA-VD

## The Epigenetic Enzyme KMT2A/MLL1 Is a Driver of Coronavirus-associated Coagulopathy

 Sriganesh B. Sharma,<sup>1</sup> William J. Melvin,<sup>1</sup> Christopher O. Audu,<sup>1</sup>
 117

 Yogendra Kanthi,<sup>2</sup> Jason S. Knight,<sup>1</sup> Nicole Rhoads,<sup>1</sup> Reheman
 118

 Adili,<sup>1</sup> Michael A. Holinstat,<sup>1</sup> Bethany B. Moore,<sup>1</sup> Peter K. Henke,<sup>1</sup>
 119

 Thomas W. Wakefield,<sup>1</sup> Katherine A. Gallagher,<sup>1</sup> Andrea T. Obi<sup>1</sup>
 120

 <sup>1</sup>University of Michigan, Ann Arbor, MI; <sup>2</sup>NHLBI, National Institutes of
 121

 Health, Bethesda, MD
 122

58

59

60

61

62

63

114

115

116


### **ARTICLE IN PRESS**

JVS-Vascular Science 2022

Objectives: Coronavirus-associated coagulopathy is postulated to be
 driven by systemic macrophage activation after severe acute respiratory
 syndrome coronavirus 2 infection and presents with an increased risk of
 thrombogenesis and hyperfibrinolysis. Previous work shows that the histone methyltransferase KMT2A/MLL1 is a key mediator of inflammatory
 sought to identify the regulation of factors important in coronavirus-associated coagulopathy by MLL1.

129 Methods: Mice with myeloid specific knockout of MLL1 (Cre<sup>+</sup>) and litter-130 mate controls (Cre<sup>-</sup>) underwent intranasal inoculation of  $2 \times 10^5$  pfu of 131 the murine coronavirus MHVA59, an established model which phenocopies severe acute respiratory syndrome coronavirus 2 infection. Splenic 132  $M\phi s$  (surrogate for circulating Mo/M $\phi s$ ) were isolated and RNA and pro-133 tein levels of urokinase (Plau; profibrinolytic), urokinase receptor (Plaur; 134 profibrinolytic), and tissue factor (F3/TF; procoagulant) were analyzed us-1353 ing quantitative reverse-transcriptase polymerase chain reaction and 136 enzyme-linked immunosorbent assay, respectively. Thromboelastography on whole blood and urokinase activity assays from mouse plasma 137 were performed. Urokinase and tissue factor activity assays were per-138 formed on plasma from human samples.

139 Results: RNA (Figure, top panel) and protein (Figure, bottom) levels of Plau, 140 Plaur, and F3 were suppressed in the splenic  $M\phi s$  harvested from sham (intra-141 nasal phosphate-buffered saline) and infected Cre<sup>+</sup> animals (white bars) compared with splenic M $\omega$ s harvested from Cre<sup>-</sup> animals (*blue bars*: Figure. 142 A). Cre<sup>-</sup> mice displayed a shortened reaction time as measured by throm-143 boelastography (Figure, B) and elevated plasma urokinase activity levels 144 (not shown). Hospitalized coronavirus disease 2019-positive patients dis-145 played elevated plasma urokinase and tissue factor activity levels (Figure, C). Conclusions: We identify a role for MLL1 for basal expression and for 146 coronavirus-mediated induction of factors important for fibrinolysis and 147 coagulation in murine  $\text{Mo}/\text{M}\phi\text{s}$  and in driving coagulopathy. Our results 148 suggest that MLL1 blockade may be an attractive strategy to combat 149 coronavirus associated coagulopathy.



Author Disclosures: S. B. Sharma: Nothing to disclose: P. K. Henke: 162 Nothing to disclose; T. W. Wakefield: Nothing to disclose; K. A. Gallagher: 163 Nothing to disclose; A. T. Obi: Nothing to disclose; W. J. Melvin: Nothing 164 to disclose; C. O. Audu: Nothing to disclose; Y. Kanthi: Honoraria, Surface 165 Oncology; Other, Pending patent to the University of Michigan on use of 166 biogases in cardiovascular disease; J. S. Knight: Nothing to disclose; N. Rhoads: Nothing to disclose; R. Adili: Nothing to disclose; M. A. Holinstat: 167 Ownership Interest, Veralox Therapeutics; Research Grant, National Insti-168 tutes of Health, Cereno Scientific; B. B. Moore: Nothing to disclose

### 170 22-VIRC-526-AHA-VD

161

169

171

# 172 Thrombospondin-5 Is Necessary for Males But Not173 Females in Hindlimb Ischemia Recovery

Melissa M. Rangel,<sup>1</sup> Corinne Bunn,<sup>2</sup> Xuerong Wang,<sup>2</sup> Xianzhong
Ding,<sup>2</sup> Kristopher Maier,<sup>3</sup> Vivian Gahtan<sup>4</sup>, <sup>1</sup>Rush University Medical
Center, Chicago, IL; <sup>2</sup>Loyola Medical Center, Chicago, IL; <sup>3</sup>Loyola
Stritch School of Medicine, Maywood, IL; <sup>4</sup>Loyola Medical Center,
Maywood, IL

Background: Ameliorating critical limb ischemia (CLI), in part, relies on
arteriogenesis and angiogenesis. We have shown that thrombospondin-5
(TSP5) is proangiogenic in vitro. The role of TSP5 in CLI and the differences
between males and females are unknown. Blood flow recovery, arteriogenesis, and angiogenesis after limb ischemia is diminished (1) in TSP5null mice compared with controls, and (2) in female compared with
male TSP5 null-mice.

Methods: Fourteen- to 16-week-old wild-type (WT; C57BI6) or TSP5-null 184 male and female mice underwent left femoral artery ligation and transec-185 tion (n = 6-9/aroup). Laser Doppler data were collected preoperatively, af-186 ter ligation, and at humane killing (day 14). Blood flow recovery was 187 expressed as a ratio of ischemic/nonischemic limb. Immunohistochemistry was performed using anti-α-smooth muscle actin on the vastus later-188 alis to quantify arteriogenesis and anti-CD31 on the gastrocnemius to 189 quantify angiogenesis. Arteriole and capillary density were determined 190 by vessel counts/5 high-power field. Data were analyzed by analysis of vari-191 ance with post hoc testing, with a *P* values of less than .05 being significant. 192

Results: TSP5-null mice had decreased blood flow recovery in males (WT 0.85  $\pm$  0.04 vs TSP5 0.48  $\pm$  0.06; P < .001) and females (WT 0.63  $\pm$ 193 0.07 vs TSP5 0.36  $\pm$  0.04; P < .01). No difference in flow recovery was 194 seen between male and female TSP5 nulls (male 0.48  $\pm$  0.06 vs female 195 0.36  $\pm$  0.04; P < .14). Arteriogenesis was impaired in male TSP5 null 196 mice (WT 3.91  $\pm$  0.24 vs TSP5 2.6  $\pm$  0.42; P < .02), but increased in females (WT 2.5  $\pm$  0.26 vs TSP5 4.35  $\pm$  0.73; P < .01). Angiogenesis was decreased in 197 TSP5-null males (WT 10.9  $\pm$  0.93 vs TSP5 7.03  $\pm$  0.84; P < .01), but not fe-198 males (WT 6.1  $\pm$  0.50 vs TSP5 5.6  $\pm$  0.80; P < .9). In contrast, flow recovery, 199 angiogenesis, and arteriogenesis were decreased in WT females 200 compared with WT males (P < .05).

Conclusions: Our findings suggest that TSP5 is relevant to vascular remodeling following hindlimb ischemia with a divergence in mechanism between males and females. TSP5 is necessary in males for arteriogenesis and angiogenesis. TSP5 in females may be suppressive of arteriogenesis and has no effect on angiogenesis. Further investigation into these sexually dimorphic adaptive processes may lead to specific targeted CLI treatments.201203204205

Author Disclosures: M. M. Rangel: Nothing to disclose; C. Bunn: Nothing to disclose; X. Wang: Nothing to disclose; X. Ding: Nothing to disclose; K. Maier: Nothing to disclose; V. Gahtan: Nothing to disclose

#### 22-VIRC-457-AHA-VD

### Microvessel Oxidative Stress Predicts Changes in Leg Function of Patients with Peripheral Arterial Disease after Supervised Exercise Therapy

**Molly Schieber**,<sup>1</sup> Sara A. Myers,<sup>2</sup> Shuai Li,<sup>1</sup> Iraklis I. Pipinos,<sup>1</sup> George Casale<sup>1</sup>. <sup>1</sup>University of Nebraska Medical Center, Omaha, NE; <sup>2</sup>University of Nebraska at Omaha, Omaha, NE

**Objective**: To evaluate baseline oxidative stress in the microvessels of patients with peripheral arterial disease (PAD) (1) in association with heme oxygenase-1 (HO-1), a critical cytoprotective molecule for oxidative stress (2) as a predictor of the functional and pathophysiologic changes that occur in response to 6 months of supervised exercise therapy (SET). We hypothesized that accumulated oxidative stress in the microvessels of PAD at baseline would predict changes in walking performance, myofiber pathology, and limb function at the end of a 6-month program of SET.

Methods: Twelve claudicating patients received six months of SET per224the American College of Cardiology/American Heart Association guide-225lines. Before and after SET, patients were evaluated for leg biomechanics,226overground walking capacity (6-minute walking distance [SMWD]), and227affected calf muscle was biopsied for quantification of HO-1 and oxidative228ated the association between HO-1 expression and carbonyl content230with correlation and multiple regression.231

**Results:** HO-1 expression and Carbonyl content were strongly associated in the microvessels (n = 1400; r = 0.98; P < .001). Increasing the carbonyl content in the microvessels of each patient was associated with increasing HO-1 expression. In a subset of patients, HO-1 expression increased more slowly with increasing carbonyl content. Pre-SET oxidative stress in microvessels was a significant predictor of SET mediated change in SMWD (r = -0.75; P = .012) and plantarflexion torque (r = 0.8571; P = .0065).

237 Conclusions: Carbonyl content (oxidative stress) in microvessels of each 238 patient was positively associated with HO-1 expression. However, in a subset of patients, HO-1 expression increased more slowly with increasing 239 carbonyl content. Baseline oxidative stress in the microvessels, which 240 may be a function of the quality of HO-1 expression, was a significant pre-241 dictor of SET-mediated change in the SMWD and plantarflexion torque. 242 The data suggest that microvessel oxidative damage may contribute 243 uniquely to calf muscle pathology and leg dysfunction in patients with PAD. 244

232

233

234

235

236